MgShell
Developing an intraocular device to reduce intravitreal injections for age-related macular degeneration.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | €1.1m | Seed | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
MgShell is an innovative startup operating in the healthcare sector, specifically in ophthalmology. The company's primary mission is to drive healthcare innovation through the development of a unique magnesium-based drug delivery platform. This technology is designed to revolutionize patient care for those suffering from retinal diseases, a niche yet significant market in the healthcare industry.
MgShell's business model is centered on the development and commercialization of this groundbreaking technology. The company aims to disrupt the ophthalmological landscape by making treatments more effective, enhancing patient adherence, and ultimately reducing healthcare costs. This approach not only benefits patients but also serves healthcare providers and insurance companies by potentially lowering the overall cost of care.
The company operates in the healthcare market, specifically targeting those suffering from retinal diseases. This market is characterized by a high demand for innovative and effective treatments, providing a significant opportunity for MgShell's unique solution.
MgShell generates revenue through the commercialization of its magnesium-based drug delivery platform. The company likely earns income from the sale of its technology to healthcare providers or through partnerships with pharmaceutical companies. The exact details of its revenue model are not publicly available.
In summary, MgShell is a healthcare startup with a unique solution for retinal disease treatment. Its innovative magnesium-based drug delivery platform has the potential to revolutionize patient care, enhance treatment adherence, and reduce healthcare costs, positioning the company for success in the healthcare market.
Keywords: Healthcare, Ophthalmology, Retinal Diseases, Drug Delivery Platform, Magnesium-Based, Innovation, Patient Care, Treatment Adherence, Cost Reduction, Pharmaceutical Partnerships.